Durect
- Country
- Ownership
- -
- Employees
- 58
- Market Cap
- -
- Introduction
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
Phase 2
Completed
- Conditions
- Postoperative Pain
- Interventions
- Drug: SABER-Bupivacaine Treatment 2aDrug: Placebo SABER-Bupivacaine Treatment 2bDrug: SABER-Bupivacaine Treatment 1aDrug: Placebo SABER-Bupivacaine Treatment 1b
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Durect
- Target Recruit Count
- 107
- Registration Number
- NCT00993798
- Locations
- 🇸🇪
Nycomed Investigational Site, Stockholm, Sweden
A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair
Phase 2
Completed
- Conditions
- HerniaSurgeryPostoperative Pain
- Interventions
- Drug: SABER-PlaceboDrug: SABER-Bupivacaine
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Durect
- Target Recruit Count
- 124
- Registration Number
- NCT00974350
A Safety and Effectiveness Study of SABER®-Bupivacaine for Pain Following Shoulder Surgery
Phase 2
Completed
- Conditions
- Postoperative Pain
- Interventions
- Drug: SABER-BupivacaineDrug: SABER-Placebo
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Durect
- Target Recruit Count
- 60
- Registration Number
- NCT00818363
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Durect
- Target Recruit Count
- 77
- Registration Number
- NCT00485225
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia
Phase 2
Completed
- Conditions
- Postherpetic NeuralgiaPain
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- Durect
- Target Recruit Count
- 60
- Registration Number
- NCT00478179
© Copyright 2025. All Rights Reserved by MedPath